Get the Stockscreener App
1.98
1.00%
-0.02
After Hours:
1.97
-0.01
-0.51%
Outlook Therapeutics Inc stock is traded at $1.98, with a volume of 1.79M.
It is down -1.00% in the last 24 hours and up +54.69% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$2.00
Open:
$2.01
24h Volume:
1.79M
Relative Volume:
0.59
Market Cap:
$87.95M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.495
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-3.41%
1M Performance:
+54.69%
6M Performance:
+7.61%
1Y Performance:
+28.57%
1-Day Range:
$1.91
$2.03
1-Week Range:
$1.91
$2.13
52-Week Range:
$0.79
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.98 | 88.84M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Analysts - MarketBeat
How Outlook Therapeutics Inc. (41ON) stock performs during market turbulenceTrade Risk Report & Free High Return Stock Watch Alerts - Newser
Is Outlook Therapeutics Inc. (41ON) stock worth buying before Fed actionMarket Trend Review & Free Real-Time Volume Trigger Notifications - Newser
Why Outlook Therapeutics Inc. (41ON) stock remains stableMarket Risk Report & Verified Short-Term Plans - Newser
Will Outlook Therapeutics Inc. (41ON) stock enhance shareholder value2025 Big Picture & Entry Point Confirmation Signals - Newser
How Outlook Therapeutics Inc. (41O) stock benefits from digital adoptionLong Setup & Weekly Market Pulse Alerts - Newser
How Outlook Therapeutics Inc. (41O) stock moves in volatile trading sessionsJuly 2025 Patterns & Fast Entry High Yield Tips - Newser
Will Outlook Therapeutics Inc. (41O) stock enhance shareholder valuePortfolio Return Report & Smart Money Movement Alerts - Newser
How Outlook Therapeutics Inc. stock benefits from tech adoptionEarnings Risk Summary & Real-Time Chart Breakout Alerts - Newser
What hedge fund moves indicate for Outlook Therapeutics Inc. (41O) stockJuly 2025 Rallies & Free Safe Entry Trade Signal Reports - Newser
How Outlook Therapeutics Inc. (41O) stock expands through international marketsOil Prices & Low Drawdown Investment Strategies - Newser
How Outlook Therapeutics Inc. (41O) stock trades under stagflationSwing Trade & Accurate Intraday Trading Signals - Newser
Will Outlook Therapeutics Inc. (41ON) stock maintain strong growthJuly 2025 Chart Watch & Free Technical Pattern Based Buy Signals - Newser
Can Outlook Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Value Summary & Daily Stock Trend Watchlist - Newser
Why institutional investors increase stakes in Outlook Therapeutics Inc. (41ON) stockWeekly Volume Report & Real-Time Market Sentiment Reports - Newser
Can Outlook Therapeutics Inc. (41O) stock stage a strong rebound this quarterEarnings Risk Summary & Weekly High Conviction Trade Ideas - Newser
Is Outlook Therapeutics Inc. (41O) stock a defensive play amid uncertaintyEarnings Overview Summary & Stock Portfolio Risk Management - Newser
Will Outlook Therapeutics Inc. (41O) stock beat value stocksMarket Trend Review & Low Risk Profit Maximizing Plans - Newser
Is Outlook Therapeutics Inc. (41ON) stock a top pick for value investors - Newser
How strong is Outlook Therapeutics Inc. (41ON) stock earnings growthPortfolio Value Summary & High Conviction Investment Ideas - Newser
Outlook Therapeutics (OTLK) Stock Analysis Report | Financials & Insights - Benzinga
Stock Report: What makes Outlook Therapeutics Inc stock attractive to growth fundsMarket Sentiment Report & Technical Entry and Exit Alerts - BỘ NỘI VỤ
Outlook Therapeutics, Inc. (OTLK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Risk Analysis: Can Outlook Therapeutics Inc. (41ON) stock resist broad market declinesQuarterly Growth Report & AI Forecasted Stock Moves - moha.gov.vn
Outlook Therapeutics Inc. (OTLK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How Outlook Therapeutics Inc. (41ON) stock trades under stagflationMarket Trend Review & Breakout Confirmation Alerts - BỘ NỘI VỤ
Can Outlook Therapeutics Inc. stock surprise with earnings upside2025 Biggest Moves & Daily Profit Maximizing Tips - BỘ NỘI VỤ
What drives Outlook Therapeutics Inc 41ON stock priceQuarterly Earnings Review & Access Risk Ratings for Every Stock - earlytimes.in
Outlook Therapeutics CEO Bob Jahr to Speak at Piper Sandler 37th Annual Healthcare Conference - Quiver Quantitative
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
What Macro Risks Could Undermine RCI Industries Technologies Limiteds ForecastMarket Rumors and News & Explosive Capital Growth Plans - earlytimes.in
Why Outlook Therapeutics Inc. stock is a must watch in 20252025 Fundamental Recap & Reliable Price Breakout Alerts - newser.com
Outlook Therapeutics’ FDA Review for ONS-5010 Resubmission - MSN
Is Outlook Therapeutics Inc. (41ON) stock expanding market penetrationJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com
Is Outlook Therapeutics Inc. (41ON) stock cheap vs fundamentalsWeekly Trading Summary & Weekly High Potential Stock Alerts - newser.com
What analyst consensus implies for Outlook Therapeutics Inc. (41O) stockWeekly Trade Report & Weekly Breakout Stock Alerts - newser.com
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):